NKGen Biotech Korea files corrected 2026 half-year report after treasury share report omission

Bitget2026/09/30 09:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NKGen Biotech Korea filed a corrected semi-annual report for the six months ended June 30, 2026.
Correction addressed an omitted treasury share report attachment.
Disclosure expanded on treasury share holdings of 5,323 common shares, including 360 shares from merger-related appraisal rights.
Added detail on 4,963 shares classified as undelivered shares tied to rehabilitation debt repayment.
Company set a statutory cancellation deadline of Sept. 5, 2027 for treasury shares acquired before the March 6, 2026 law change.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NKGen Biotech Korea Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930000644), on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NKGen Biotech Korea files corrected 2026 half-year report after treasury share report omission

You may also like

Crypto prices